Table 3. Multivariate Logistic Regression of the Association Between Variables and SARS-CoV-2 Immunogobulin G Anti-RBD Seroconversion or Convalescent Serum Levels 2 Weeks After Second BNT162b2 Dose.
| Variable | Anti-RBD seroconversiona | Anti-RBD reaching median convalescent serum levelb | ||
|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | |
| Age | 1.01 (0.97-1.06) | .58 | 0.98 (0.94-1.01) | .22 |
| Male sex | 1.33 (0.25-7.24) | .74 | 0.45 (0.16-1.28) | .13 |
| Vaccine reactogenicityc | 22.86 (2.46-212.83) | .006 | 1.96 (0.70-5.50) | .20 |
Abbreviations: OR, odds ratio; IgG, immunoglobulin G; RBD, receptor binding domain.
a
Seroconversion threshold represents a positive test and is 0.186 for anti-RBD.
b
The median convalescent serum level is taken from COVID-19 survivors 21 to 115 days postsymptom onset and is 1.25 for anti-RBD antibodies.
c
Vaccine reactogenicity in patients receiving hemodialysis (n = 70) was binary in the model based on the presence of any of the following symptoms within 14 days after the second vaccine dose: pain, redness, swelling, fever, chills, fatigue, nausea/vomiting, diarrhea, myalgia, and joint pain.